281 related articles for article (PubMed ID: 9521772)
21. Mutations that alter the activity of the Rous sarcoma virus protease.
Grinde B; Cameron CE; Leis J; Weber IT; Wlodawer A; Burstein H; Bizub D; Skalka AM
J Biol Chem; 1992 May; 267(14):9481-90. PubMed ID: 1315755
[TBL] [Abstract][Full Text] [Related]
22. Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease.
Tomaszek TA; Moore ML; Strickler JE; Sanchez RL; Dixon JS; Metcalf BW; Hassell A; Dreyer GB; Brooks I; Debouck C
Biochemistry; 1992 Oct; 31(42):10153-68. PubMed ID: 1420138
[TBL] [Abstract][Full Text] [Related]
23. Kinetics of the dimerization of retroviral proteases: the "fireman's grip" and dimerization.
Ingr M; Uhlíková T; Strísovský K; Majerová E; Konvalinka J
Protein Sci; 2003 Oct; 12(10):2173-82. PubMed ID: 14500875
[TBL] [Abstract][Full Text] [Related]
24. Combining mutations in HIV-1 protease to understand mechanisms of resistance.
Mahalingam B; Boross P; Wang YF; Louis JM; Fischer CC; Tozser J; Harrison RW; Weber IT
Proteins; 2002 Jul; 48(1):107-16. PubMed ID: 12012342
[TBL] [Abstract][Full Text] [Related]
25. Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap.
Gustchina A; Weber IT
FEBS Lett; 1990 Aug; 269(1):269-72. PubMed ID: 2201571
[TBL] [Abstract][Full Text] [Related]
26. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.
Hong L; Koelsch G; Lin X; Wu S; Terzyan S; Ghosh AK; Zhang XC; Tang J
Science; 2000 Oct; 290(5489):150-3. PubMed ID: 11021803
[TBL] [Abstract][Full Text] [Related]
27. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV.
Kervinen J; Lubkowski J; Zdanov A; Bhatt D; Dunn BM; Hui KY; Powell DJ; Kay J; Wlodawer A; Gustchina A
Protein Sci; 1998 Nov; 7(11):2314-23. PubMed ID: 9827997
[TBL] [Abstract][Full Text] [Related]
28. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
[TBL] [Abstract][Full Text] [Related]
29. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.
Hoog SS; Towler EM; Zhao B; Doyle ML; Debouck C; Abdel-Meguid SS
Biochemistry; 1996 Aug; 35(32):10279-86. PubMed ID: 8756683
[TBL] [Abstract][Full Text] [Related]
30. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease.
Prabu-Jeyabalan M; Nalivaika E; Schiffer CA
J Mol Biol; 2000 Sep; 301(5):1207-20. PubMed ID: 10966816
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
[TBL] [Abstract][Full Text] [Related]
32. Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis.
Hong L; Tang J
Biochemistry; 2004 Apr; 43(16):4689-95. PubMed ID: 15096037
[TBL] [Abstract][Full Text] [Related]
33. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease.
Menéndez-Arias L; Weber IT; Soss J; Harrison RW; Gotte D; Oroszlan S
J Biol Chem; 1994 Jun; 269(24):16795-801. PubMed ID: 8207003
[TBL] [Abstract][Full Text] [Related]
34. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
35. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
36. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
Mahalingam B; Louis JM; Hung J; Harrison RW; Weber IT
Proteins; 2001 Jun; 43(4):455-64. PubMed ID: 11340661
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 protease substrate-groove: Role in substrate recognition and inhibitor resistance.
Laco GS
Biochimie; 2015 Nov; 118():90-103. PubMed ID: 26300060
[TBL] [Abstract][Full Text] [Related]
38. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
Calugi C; Guarna A; Trabocchi A
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
[TBL] [Abstract][Full Text] [Related]
39. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
Chen Z; Li Y; Chen E; Hall DL; Darke PL; Culberson C; Shafer JA; Kuo LC
J Biol Chem; 1994 Oct; 269(42):26344-8. PubMed ID: 7929352
[TBL] [Abstract][Full Text] [Related]
40. Proteolytic activation of recombinant pro-memapsin 2 (pro-beta-secretase) studied with new fluorogenic substrates.
Ermolieff J; Loy JA; Koelsch G; Tang J
Biochemistry; 2000 Oct; 39(40):12450-6. PubMed ID: 11015226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
